An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious Puberty
Phase of Trial: Phase IV
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Leuprorelin (Primary)
- Indications Precocious puberty
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda
- 26 Feb 2018 Planned End Date changed from 27 Feb 2018 to 30 Sep 2018.
- 26 Feb 2018 Planned primary completion date changed from 27 Feb 2018 to 30 Sep 2018.
- 30 Jun 2017 Status changed from not yet recruiting to recruiting.